1176 related articles for article (PubMed ID: 33761203)
21. Audio Interview: How Well Are Covid-19 Vaccines Working?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
[No Abstract] [Full Text] [Related]
22. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
[No Abstract] [Full Text] [Related]
23. Novavax offers first evidence that COVID vaccines protect people against variants.
Callaway E; Mallapaty S
Nature; 2021 Feb; 590(7844):17. PubMed ID: 33510489
[No Abstract] [Full Text] [Related]
24. Evolving threat.
Kupferschmidt K
Science; 2021 Aug; 373(6557):844-849. PubMed ID: 34413220
[No Abstract] [Full Text] [Related]
25. Beyond Omicron: what's next for COVID's viral evolution.
Callaway E
Nature; 2021 Dec; 600(7888):204-207. PubMed ID: 34876665
[No Abstract] [Full Text] [Related]
26. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
Liu Y; Liu J; Xia H; Zhang X; Zou J; Fontes-Garfias CR; Weaver SC; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Jul; 385(5):472-474. PubMed ID: 33979486
[No Abstract] [Full Text] [Related]
27. COVID vaccines slash viral spread - but Delta is an unknown.
Mallapaty S
Nature; 2021 Aug; 596(7870):17-18. PubMed ID: 34321643
[No Abstract] [Full Text] [Related]
28. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.
Edara VV; Hudson WH; Xie X; Ahmed R; Suthar MS
JAMA; 2021 May; 325(18):1896-1898. PubMed ID: 33739374
[TBL] [Abstract][Full Text] [Related]
29. Audio Interview: Protecting the Immunosuppressed against Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 May; 384(21):e88. PubMed ID: 34042395
[No Abstract] [Full Text] [Related]
30. Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.
Rubin EJ; Baden LR; Abraham J; Morrissey S
N Engl J Med; 2021 Mar; 384(10):e48. PubMed ID: 33704945
[No Abstract] [Full Text] [Related]
31. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
32. Audio Interview: Understanding the Omicron Variant of SARS-CoV-2.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2022 Feb; 386(8):e27. PubMed ID: 35196435
[No Abstract] [Full Text] [Related]
33. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
[No Abstract] [Full Text] [Related]
34. Could new COVID variants undermine vaccines? Labs scramble to find out.
Callaway E
Nature; 2021 Jan; 589(7841):177-178. PubMed ID: 33432212
[No Abstract] [Full Text] [Related]
35. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
36. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination.
Abbasi J
JAMA; 2021 Sep; 326(10):901. PubMed ID: 34519816
[No Abstract] [Full Text] [Related]
38. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Shinde V; Bhikha S; Hoosain Z; Archary M; Bhorat Q; Fairlie L; Lalloo U; Masilela MSL; Moodley D; Hanley S; Fouche L; Louw C; Tameris M; Singh N; Goga A; Dheda K; Grobbelaar C; Kruger G; Carrim-Ganey N; Baillie V; de Oliveira T; Lombard Koen A; Lombaard JJ; Mngqibisa R; Bhorat AE; Benadé G; Lalloo N; Pitsi A; Vollgraaff PL; Luabeya A; Esmail A; Petrick FG; Oommen-Jose A; Foulkes S; Ahmed K; Thombrayil A; Fries L; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Robertson A; Neal S; Cho I; Glenn GM; Dubovsky F; Madhi SA;
N Engl J Med; 2021 May; 384(20):1899-1909. PubMed ID: 33951374
[TBL] [Abstract][Full Text] [Related]
39. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
40. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design.
Groves DC; Rowland-Jones SL; Angyal A
Biochem Biophys Res Commun; 2021 Jan; 538():104-107. PubMed ID: 33199022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
